first-line treatment of inhl or mcl patients with br or r-chop/r-cvp: bright 5-year follow-up study
Published 7 years ago • 171 plays • Length 5:07Download video MP4
Download video MP3
Similar videos
-
3:01
treating indolent and mantle cell lymphoma: results of the bright 5 year follow up study
-
1:49
dr. flinn on long-term follow-up of bright study in mcl and inhl
-
5:55
ian flinn, md: bendamustine plus rituxmab outperforms r-chop in long-term bright follow-up
-
2:28
highlights on first-line treatment of mantle cell lymphoma: primary results from shine
-
3:10
is there a benefit to rituximab maintenance after first-line bendamustine-rituximab for mcl?
-
2:03
chemotherapy for mantle cell lymphoma: br vs. r-chop - blood cancers video library
-
4:42
the triangle study: ibrutinib maintenance - blood cancers video library
-
1:10
car-t therapy for high-risk mcl patients
-
1:46
btk inhibitors continue to improve survival in mantle cell lymphoma
-
1:58
should we transplant or not in frontline therapy for mcl?
-
1:31
acalabrutinib in combination with bendamustine & rituximab in treatment-naïve or r/r mcl
-
31:39
lymphoma | 2022 oneoncology conference
-
14:25
mathias rummel, md, phd: bendamustine-rituximab "stil" beats r-chop for indolent lymphomas
-
5:28
first results of a prospective bendamustine/rituximab trial in patients with mcl
-
1:26
btk inhibitor use proves beneficial in mantle cell lymphoma treatment
-
1:50
acalabrutinib and rituximab as first-line therapy for older patients with mcl
-
4:11
first-line treatment for mantle cell lymphoma
-
1:47
challenges in using car-t therapy & btk inhibitors in patients with r/r mcl
-
0:50
exploring subsets of patients with mantle cell lymphoma